Abedon Stephen T
Department of Microbiology, The Ohio State University, Mansfield, Ohio, USA.
Phage (New Rochelle). 2022 Jun 1;3(2):95-97. doi: 10.1089/phage.2022.0012. Epub 2022 Jun 16.
Over the past decade I, with collaborators, have authored a number of publications outlining what in the first of these I described as "Phage therapy best practices"-phage therapy being the use of bacterial viruses (bacteriophages) to treat bacterial infections, such as clinically. More generally, this is phage-mediated biocontrol of bacteria, including of bacteria that can contaminate foods. For the sake of increasing accessibility, here I gather some of these suggestions, along with some frustrations, into a single place, while first providing by way of explanation where they, and I, come from scientifically. Although in my opinion phage therapy and phage-mediated biocontrol are both sound approaches toward combating unwanted bacteria, I feel at the same time that the practice of especially phage therapy research could be improved. I supply also, as supplemental material, a list of ∼100 English language 2000-and-later publications providing primary descriptions of phage application to humans.
在过去十年里,我与合作者撰写了多篇论文,概述了我在第一篇论文中所描述的“噬菌体疗法最佳实践”——噬菌体疗法是指利用细菌病毒(噬菌体)来治疗细菌感染,比如临床上的细菌感染。更广泛地说,这是噬菌体介导的对细菌的生物控制,包括对可能污染食物的细菌的控制。为了让更多人能够了解,我在此将其中一些建议以及一些令人沮丧的情况汇总到一处,同时首先从科学角度解释这些建议以及我本人的观点来源。尽管在我看来,噬菌体疗法和噬菌体介导的生物控制都是对抗有害细菌的合理方法,但我同时觉得,尤其是噬菌体疗法的研究实践还有待改进。我还提供了一份约100篇2000年及以后发表的英文出版物清单作为补充材料,这些出版物主要描述了噬菌体在人类身上的应用。